Key result
Supera interwoven nitinol stents yield ~13% 12-month target lesion revascularization in femoropopliteal lesions.
Why the study?
The Supera stent is an interwoven nitinol stent with enhanced flexibility and radial strength compared to conventional laser-cut stents. This study evaluated patency and target lesion revascularization after Supera stent implantation for femoropopliteal lesions in an unselected, real-world patient cohort.
Does Supera interwoven nitinol stent implantation achieve favorable patency and target lesion revascularization rates in unselected patients with femoropopliteal peripheral arterial occlusive disease?
Observational (n=649)
No
Does Supera interwoven nitinol stent implantation achieve favorable patency and target lesion revascularization rates in unselected patients with femoropopliteal peripheral arterial occlusive disease?
Answers are grounded in this paper and cite their sources.
In a large real-world cohort of 649 patients with femoropopliteal artery disease, interwoven nitinol Supera stent implantation demonstrated high technical success (99.1%) and acceptable midterm target lesion revascularization rates (13.3% at 1 year, 23.4% at 2 years), while adjunctive drug-coated balloon use provided no additional benefit in reducing revascularization.
Background: Numerous stents have been developed for the treatment of femoropopliteal lesions.The Supera stent is a self-expanding nitinol stent composed of six helically interwoven wires with a closed-cell design.Unlike conventional laser-cut stents, its unique structure provides enhanced flexibility and radial strength.Purpose: To evaluate patency and target lesion revascularization (TLR) after Supera stent implantation for femoropopliteal lesions in an unselected, real-world patient cohort.Methods: This retrospective study included patients treated with a Supera stent between January 2010 and January 2016 for peripheral arterial occlusive disease of all clinical categories and a follow-up of 24 months.The primary endpoint was TLR at 12 months.Secondary endpoints included TLR at 24 months, primary patency, major amputation, changes in ankle-brachial index (ABI) and Rutherford-Becker class (RBC), and predictors of restenosis and TLR.Results: A total of 649 patients were included; 69.8% were treated for intermittent claudication.TLR rates were 13.3% at 12 months and 23.4% at 24 months.Drug-coated balloon (DCB) use had no significant effect on TLR (p=0.20).Primary patency was 65.6% at 12 months and 43.0% at 24 months.ABI and RBC improved significantly, while the major amputation rate was 0.9% at 24 months.Longer stent length and DCB use predicted restenosis.Critical limb-threatening ischemia (CLTI) predicted TLR, whereas good runoff and lower calcification (PACSS) were protective.Conclusion: Supera stent implantation achieved favorable acute and midterm outcomes.Adjunctive DCB use did not reduce TLR rates.
No takes yet. Share an insight, caveat, or question.
Noory et al. (2026) conducted an observational in Peripheral arterial occlusive disease with femoropopliteal lesions (n=649). Supera interwoven nitinol stent implantation was evaluated on Target lesion revascularization (TLR) at 12 months. Supera interwoven nitinol stent implantation in femoropopliteal lesions resulted in a 12-month target lesion revascularization rate of 13.3% and a primary patency rate of 65.6%.
Synapse has enriched 10 related papers. Consider them for comparative context: